R. Paul Fonteyne - Director at Apellis Pharmaceuticals, Inc.

Insider Transactions and Holdings

Security	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class	Underlying Amount
Stock Option (Right to Buy)	11.2K	$381K	$66.30	Jan 1, 2025	Direct	Common Stock
Common Stock	22.7K	$314K	$13.85	Jan 1, 2025	Direct

Showing 1 to 2 of 2 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.